Menu
Not yet recruiting NCT06564883

Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women

Phase III Interventional Vaginismus Vaginal Atrophy Menopause

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 0.20% sodium hyaluronate gel.
Who it may be relevant to
Registry conditions: Vaginismus, Vaginal Atrophy, Menopause. Basic parameters: No limits · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Clinical Evaluation of Hydration and Acceptability of the Genital and Cutaneous Mucosa of a Vaginal Moisturizer in Vaginal Dryness in Menopausal Women

Overview

Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours. Hyaluronic Acid promotes vaginal moisture, providing symptom relief in various situations such as: * Vaginismus and other sexual dysfunctions related to penetration * Users of hormonal contraceptives with lubrication loss * Postpartum and lactational period * Post antibacterial or antifungal therapies * During systemic oncological treatments (chemotherapy, radiotherapy, hormone therapy) * Climacteric (urogenital atrophy) * Post urogynecological surgeries (correction of urinary incontinence, genital dystopias, etc.) * Post vulvovaginal abrasive, chemical, laser, or high-frequency therapies * Post cosmetic and genital rejuvenation therapies

Interventions

  • Device 0.20% sodium hyaluronate gel
    Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.

Primary outcome measures

  • Verify the hydration of the cutaneous and genital mucosa after using hyaluronic acid-based vaginal gel [Time frame: 22 days]
  • Verify the acceptability of the cutaneous and genital mucosa after using hyaluronic acid-based vaginal gel [Time frame: 22 days]
Secondary outcome measures (3)
  • Relief of pruritus after using hyaluronic acid-based vaginal gel [Time frame: 22 days]
  • Verify the maintenance of pH after using Hyaluronic Acid when applied under recommended conditions of use through gynecologist follow-up during the use. [Time frame: 22 days]
  • Verify the maintenance of vaginal microbiota after using Hyaluronic Acid when applied under recommended conditions of use through gynecologist follow-up during the use. [Time frame: 22 days]

Eligibility criteria

Inclusion criteria

  • Healthy research participants, with an active sexual life;
  • Intact skin and mucosa in the test region;
  • Participants vaccinated for COVID-19 (Corona virus Disease).
  • Agreement to adhere to the study procedures and requirements and attend the institute on the day(s) and time(s) determined for the assessments;
  • Ability to consent to participate in the study;
  • Menopausal participants of any age, without systemic or topical hormone replacement therapy in the last 6 months
  • Presenting mild to moderate vaginal dryness (≥0.5 and <7.5) - according to the Visual Analogic Scale
  • Healthy research participants, with an active sex life (at least once a week)

Exclusion criteria

  • Skin pathology in the area of product application;
  • Decompensated Diabetes Mellitus (TBD by the institute together with the sponsor);
  • Immune insufficiency;
  • Current use of the following topical or systemic medications: corticosteroids, immunosuppressants and antihistamines;
  • Skin diseases: vitiligo, psoriasis, atopic dermatitis;
  • Previous reaction to the category of the product tested;
  • Other illnesses or medications that may directly interfere with the study or put the health of the research participant at risk.
  • Have used vaginal moisturizing creams and/or intimate lubricants 5 days before the initial study visit;
  • Have had sexual intercourse at least 48 hours before the initial study visit;
  • Have been diagnosed with a urogenital or vaginal infection in the last 30 days;
  • Have used topical or systemic antibiotics, antifungals, hormone-based creams or treatment for vaginal atrophy in the last 30 days.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06564883 · BS-GIMM24

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗